Daiichi Sankyo and LYSA-LYSARC-CALYM Enter Research Collaboration for Valemetostat in Patients with Relapsed/Refractory B-Cell Lymphoma
Phase 2 trial to evaluate valemetostat in patients with five disease subtypes along with a planned robust translational research program...






